Market Reports
![]() |
|
EXECUTIVE SUMMARY i. Peripheral Vascular Stents a. Aortic Aneurysm Stent-Grafts b. Carotid Artery Stents c. Lower-Extremity Arterial Stents d. Renal Artery Stents e. Transjugular Intrahepatic Portosystemic Shunts ii. Combined Market Analysis Exhibit ES-1: Aortic Aneurysm Stent-Grafts, Market Forecast, 2004-2010 Exhibit ES-2: Carotid Artery Stents/Embolic Protection Systems, Market Forecast, 2004-2010 Exhibit ES-3: Lower-Extremity Stents, Market Forecast, 2004-2010 Exhibit ES-4: Renal Artery Stents, Market Forecast, 2004-2010 Exhibit ES-5: Transjugular Intrahepatic Portosystemic Shunts, Market Forecast, 2004-2010 Exhibit ES-6: Peripheral Vascular Stenting, Procedure Volumes Forecast, 2004-2010 Exhibit ES-7: Peripheral Vascular Stents, Market Forecast, 2004-2010 1. CURRENT AND EMERGING STENTING TECNOLOGIES 1.1 Stent Design 1.1.1 Vascular Stents 1.1.2 Nonvascular Stents 1.1.3 Stent Deployment Mechanisms 1.2 Stent Materials 1.2.1 Metal Stents 1.2.1.1 Absorbable Magnesium Alloys 1.2.1.2 Cobalt Alloys 1.2.1.3 Nickel-Titanium Alloys 1.2.1.4 Stainless Steel 1.2.2 Standard Polymeric Stents 1.2.3 Biodegradable Polymeric Stents 1.3 Stent Coatings 1.3.1 Radiopacity Enhancement 1.3.2 Biocompatibility Enhancement 1.3.3 Active Therapeutic Enhancement 1.3.3.1 Drug-Eluting Stents 1.3.3.1.1 Anti-Restenotic Drug-Eluting Stents 1.3.3.1.2 Drug Delivery Techniques 1.3.4 Stent Coverings and Linings Exhibit 1-1: Selected Biomedical, Clinical, and Technical Stent Requirements Exhibit 1-2: Advantages and Disadvantages of Selected Vascular Stent Designs Exhibit 1-3: Advantages and Disadvantages of Metal Stent Materials Exhibit 1-4: Selected Polymeric Stent Materials Exhibit 1-5: Selected Characteristics of Antirestenosis Agents Used in Drug-Eluting Stents Exhibit 1-6: Advantages and Disadvantages of Nonresorbable and Biodegradable Polymeric Drug Carriers for Drug-Eluting Stents 2. PERIPHERAL VASCULAR STENTS MARKET 2.1 Anatomy and Physiology of the Vascular System 2.2 Peripheral Vascular Conditions Targeted by Stenting 2.2.1 Aortic Aneurysm 2.2.1.1 Treatment 2.2.1.1.1 Watchful Waiting 2.2.1.1.2 Surgical Intervention 2.2.1.1.3 Endovascular Repair of Abdominal Aortic Aneurysm 2.2.1.1.4 Endovascular Repair of Thoracic Aortic Aneurysm 2.2.1.1.5 Procedure Volumes 2.2.2 Carotid Artery Stenosis and Ischemic Stroke 2.2.2.1 Etiology 2.2.2.2 Carotid Artery Stenosis and Cerebral Thrombosis 2.2.2.3 Treatment 2.2.2.3.1 Carotid Endarterectomy 2.2.2.3.2 Carotid Artery Stenting 2.2.2.3.2.1 Procedure Volumes 2.2.3 Lower-Extremity Arterial Occlusion 2.2.3.1 Treatment 2.2.3.1.1 Surgical Revascularization 2.2.3.1.1.1 Aortoiliofemoral Bypass Grafting 2.2.3.1.1.2 Femoropopliteal Bypass Grafting 2.2.3.1.1.3 Distal Tibial-Peroneal Bypass Grafting 2.2.3.1.1.4 Thromboendarterectomy 2.2.3.1.2 Interventional Treatment 2.2.3.1.2.1 Percutaneous Transluminal Angioplasty 2.2.3.1.3 Lower-Extremity Stenting Techniques 2.2.3.1.3.1 Iliac Artery Stenting 2.2.3.1.3.2 Femoropopliteal Artery Stenting 2.2.3.1.3.3 Infrapopliteal Stenting 2.2.3.1.3.4 Procedure Volumes 2.2.4 Renal Artery Stenosis 2.2.4.1 Treatment 2.2.4.1.1 Surgical Revascularization 2.2.4.1.2 Renal Artery Angioplasty 2.2.4.1.3 Renal Artery Stenting 2.2.4.1.3.1 Emerging Renal Drug-Eluting Stent Technologies 2.2.4.1.3.2 Procedure Volumes 2.2.5 Portal Hypertension and Variceal Bleeding 2.2.5.1 Treatment 2.2.5.1.1 Surgical Decompressive Shunting 2.2.5.1.2 Transjugular Intrahepatic Portosystemic Shunting 2.2.6 Other Applications of Peripheral Vascular Stenting 2.2.6.1 Subclavian Artery Stenosis Treatment 2.2.6.2 Venous Stenting 2.3 Market Analysis 2.3.1 Aortic Aneurysm Stent-Grafts 2.3.1.1 Products 2.3.1.1.1 Bolton Medical/CH-Werfen Hospital Group 2.3.1.1.2 Boston Scientific 2.3.1.1.3 Cook Group 2.3.1.1.4 Cordis/Johnson & Johnson 2.3.1.1.5 Endologix 2.3.1.1.6 W. L. Gore & Associates 2.3.1.1.7 LeMaitre Vascular 2.3.1.1.8 Medtronic 2.3.1.1.9 Vascutek/Terumo 2.3.1.2 Market Forecast 2.3.1.2.1 Competitive Analysis 2.3.2 Carotid Artery Stents 2.3.2.1 Products 2.3.2.1.1 Abbott Vascular/Abbott Laboratories 2.3.2.1.2 Bard Peripheral Vascular/C. R. Bard 2.3.2.1.3 Boston Scientific 2.3.2.1.4 Cordis/Johnson & Johnson 2.3.2.1.5 ev3 2.3.2.1.6 Guidant/Boston Scientific 2.3.2.1.7 Medtronic 2.3.2.2 Market Forecast 2.3.2.2.1 Competitive Analysis 2.3.3 Lower-Extremity Arterial Stents 2.3.3.1 Products 2.3.3.1.1 Iliac Artery Stents 2.3.3.1.1.1 Boston Scientific 2.3.3.1.1.2 Cordis/Johnson & Johnson 2.3.3.1.1.3 ev3 2.3.3.1.1.4 Vascular Architects 2.3.3.1.2 Femoropopliteal Stents 2.3.3.1.2.1 Abbott Vascular/Abbott Laboratories 2.3.3.1.2.2 Bard Peripheral Vascular/C. R. Bard 2.3.3.1.2.3 Cook Group 2.3.3.1.2.4 Cordis/Johnson & Johnson 2.3.3.1.2.5 Edwards Lifesciences 2.3.3.1.2.6 ev3 2.3.3.1.2.7 W. L. Gore & Associates 2.3.3.1.2.8 Guidant/Boston Scientific 2.3.3.1.2.9 Vascular Architects 2.3.3.1.3 Infrapopliteal Stents 2.3.3.1.3.1 BIOTRONIK 2.3.3.1.3.2 Sorin Biomedica Cardio/Sorin Group 2.3.3.2 Market Forecast 2.3.3.2.1 Competitive Analysis 2.3.4 Renal Artery Stents 2.3.4.1 Products 2.3.4.1.1 Cordis/Johnson & Johnson 2.3.4.1.2 Medtronic 2.3.4.1.3 ev3 2.3.4.2 Market Forecast 2.3.4.2.1 Competitive Analysis 2.3.5 Transjugular Intrahepatic Portosystemic Shunts 2.3.5.1 Products 2.3.5.2 Market Forecast 2.3.5.2.1 Competitive Analysis Exhibit 2-1: 2005, Aortic Aneurysm, Facts and Figures Exhibit 2-2: Endovascular Aortic Aneurysm Repair, Procedure Volumes Forecast, 2004-2010 Exhibit 2-3: 2005, Carotid Artery Stenosis, Facts and Figures Exhibit 2-4: Carotid Artery Stenting, Procedure Volumes Forecast, 2004-2010 Exhibit 2-5: 2005, Lower-Extremity Occlusive Artery Disease, Facts and Figures Exhibit 2-6: Lower-Extremity Primary and Adjuvant Stenting, Procedure Volumes Forecast, 2004-2010 Exhibit 2-7: 2005, Renal Artery Stenosis, Facts and Figures Exhibit 2-8: Renal Artery Stenting, Procedure Volumes Forecast, 2004-2010 Exhibit 2-9: Acute Portal Hypertension and Variceal Bleeding, Facts and Figures Exhibit 2-10: Transjugular Intrahepatic Portosystemic Shunting, Procedure Volumes Forecast, 2004-2010 Exhibit 2-11: Peripheral Vascular Stenting, Procedure Volumes Forecast, 2004-2010 Exhibit 2-12: Peripheral Vascular Stenting Devices, Market Forecast, 2004-2010 Exhibit 2-13: 2006, Selected Current and Emerging Aortic Aneurysm Stent-Grafts Exhibit 2-14: Aortic Aneurysm Stent-Grafts, Market Forecast, 2004-2010 Exhibit 2-15: 2005, Abdominal Aortic Aneurysm Stent-Grafts Market, Share by Supplier Exhibit 2-16: 2006, Selected Current and Emerging Carotid Artery Stents and Embolic Protection Systems Exhibit 2-17: Carotid Artery Stents/Embolic Protection Systems, Market Forecast, 2004-2010 Exhibit 2-18: 2005, Carotid Artery Stents/Embolic Protection Systems Market, Share by Supplier Exhibit 2-19: 2006, Selected Current and Emerging Lower-Extremity Artery Stents Exhibit 2-20: Lower-Extremity Stents, Market Forecast, 2004-2010 Exhibit 2-21: 2005, Iliac Artery Stents Market, Share by Supplier Exhibit 2-22: 2005, Femoropopliteal Stents Market, Share by Supplier Exhibit 2-23: 2006, Selected Current and Emerging Renal Artery Stents Exhibit 2-24: Renal Artery Stents, Market Forecast, 2004-2010 Exhibit 2-25: 2005, Renal Artery Stents Market, Share by Supplier Exhibit 2-26: 2006, Selected Transjugular Intrahepatic Portosystemic Shunts Exhibit 2-27: Transjugular Intrahepatic Portosystemic Shunts, Market Forecast, 2004-2010 Exhibit 2-28: 2005, Transjugular Intrahepatic Portosystemic Shunts Market, Share by Supplier 3. COMPANY PROFILES 3.1 Abbott Laboratories 3.2 C. R. Bard, Inc. 3.3 Boston Scientific Corporation 3.4 Cook Group 3.5 Cordis Corporation/Johnson & Johnson 3.6 ev3, Inc. 3.7 W. L. Gore & Associates, Inc. 3.8 Guidant Corporation/Boston Scientific Corporation 3.9 Medtronic, Inc. *** This is a partial list of companies, for a full listing request it ***
* Single License allows for report sharing within one company location.
Stents are implantable devices designed to serve as endoluminal scaffolds in the recanalization of occluded or structurally compromised vascular and nonvascular circulatory pathways in various organs and tissues of the human body. Peripheral vascular applications for stenting include aortic aneurysm repair, carotid artery stenting, iliac artery stenting, femoropopliteal stenting, infrapopliteal stenting, renal artery stenting, and transjugular intrahepatic portosystemic shunting. In 2005, U.S. sales of peripheral vascular stents totaled approximately $918 million. Over the forecast period covered by this report, this figure is expected to increase at a compound annual rate of 14%, reaching approximately $1.8 billion in the year 2010.
This report from Medtech Insight includes analyses of products, technologies, current and forecast markets, competitors, and opportunities in the U.S. peripheral vascular stents market. Topics discussed in this report include current and emerging stenting technologies (e.g., stent design, materials, and coatings), a discussion of the anatomy and physiology of the human vascular system, abdominal and thoracic aortic aneurysm, carotid artery stenosis, lower-extremity arterial occlusion, renal artery stenosis, and portal hypertension.
Abbott Laboratories
C. R. Bard, Inc.
Boston Scientific Corporation
Cook Group
Cordis Corporation/Johnson & Johnson
ev3, Inc.
W. L. Gore & Associates, Inc
Guidant Corporation/Boston Scientific Corporation
Medtronic, Inc.
+ MORE
** Corporate License allows for report sharing within all company locations.
This report is listed in the following markets:
Drug Delivery and Vascular

